Trial TCTR20210722003
Publication Nanthapisal S, Vaccine, 2022
Primary outcome on the report: 1) GMR of sVNT against wild type and delta variant; 2) anti-S-RBD IgG, comparing low dose to standard dose at day 14 and 28 after booster

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.